Evaluating results from the multiple myeloma patient subset treated with denosumab or zoledronic acid in a randomized phase 3 trial

In a phase 3 trial of denosumab vs zoledronic acid in patients (n=1776) with bone metastases and solid tumors or multiple myeloma, denosumab was superior to zoledronic acid for the primary end point of prevention of skeletal-related events. There was no difference in overall survival between the two...

Descripción completa

Detalles Bibliográficos
Autores principales: Raje, N, Vadhan-Raj, S, Willenbacher, W, Terpos, E, Hungria, V, Spencer, A, Alexeeva, Y, Facon, T, Stewart, A K, Feng, A, Braun, A, Balakumaran, A, Roodman, G D
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2016
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4742634/
https://www.ncbi.nlm.nih.gov/pubmed/26745852
http://dx.doi.org/10.1038/bcj.2015.96

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4742634/
https://www.ncbi.nlm.nih.gov/pubmed/26745852
http://dx.doi.org/10.1038/bcj.2015.96

Ejemplares similares